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Summary
Objectives: To assess the influence of different factors on health-related QOL in
adults with epilepsy in Moscow, Russia.
Method: We evaluated quality of life in 242 patients (98 de novo and 144 previously
inadequately treated) by using QOLIE-31. Partial cryptogenic or symptomatic epilepsy
was diagnosed in 214 patients, in 28-idiopathic generalized epilepsy. Stepwise
regression analysis was performed to assess the influence of different factors on QOL.
Results: In patients with epilepsy in Russia the total score of QOLIE-31 was rather low–
—42.13  4.14. Relationship of quality of life (total score) and frequency of seizures
and duration of disease was analyzed. Frequency of seizures was the most significant
parameter related to QOL (R = 0.46 with total score). Duration of disease also
correlated with QOL score (R = 0.24 with total score). Significant but rather weak
association (link) between frequency of seizures and almost all of subscales of quality
of life was noticed. Duration of epilepsy correlated with less number of subscales:
Energy/fatigue, Medication effects, Social functioning, Overall QOL subscales. When
factors influencing on QOL were separately analyzed in newly diagnosed and pre-
viously treated patients frequency of seizures was the most important parameter in
both groups.
Conclusions: Frequency of seizures is the most important factor influencing on QOL in
adults with epilepsy (newly diagnosed and previously treated).
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +7 916 1888427
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Epilepsy is a chronic condition with numerous social
and psychological consequences. High prevalence of. Published by Elsevier Ltd. All rights reserved.
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social significance of disease.12,22,26
It is important that epilepsy is potentially curable
and remission may be achieved in relatively large
proportion of patients.16 Brodie and Dichter4
showed that seizures can be completely controlled
in 60—70% of patients. Adequate therapy improves
medical and social prognosis of patients, possibility
of every individual to implement his or her abilities.
As demonstrated by several studies,28—30 quality of
life (QOL) is worse in epileptic patients than in the
general population. For instance, patients with epi-
lepsy had significantly lower scores compared with
healthy persons in six domains of the SF-36 in a
prospective observational study of patients with
partial or generalized epileptic seizures.29
Several authors investigated the influence of
different factors on quality of life. QOL of patients
with epilepsy depended upon effectiveness of anti-
epileptic therapy and disease duration; QOL was
poor in patients with partial seizures; the best
QOL scores were found in patients who were free
from seizures.24,27 Frequency of seizures seemed to
be one of the most relevant determinants of poor
quality-of-life scores.13,19 Being seizure free was a
necessary but not sufficient condition to have a good
quality of life.2,28 Still, HRQL scores for seizure-free
patients were similar to the general population.17
Overall, quality of life was worse in patients with
epilepsy than in the general population; it was
comparable or worse in patients with epilepsy than
that in patients with other chronic conditions; and it
was similar to that of healthy persons when patients
with epilepsy are well-controlled. Depression con-
tributed to the poor QOL in epilepsy5,8,23 and was a
powerful predictor of QOL in patients with farm-
acoresistant epilepsy.3 These data were obtained
mostly in the USA and Western Europe. Better
understanding of QOL in people with epilepsy leav-
ing in different countries is important: a large num-
ber of cultural, ethnic, economical differences have
their impact on the QOL.
The aim of the present study was to identify main
factors influencing on the HRQOL in the cohort of
patients with epilepsy in Russia. Up to now there are
no published papers about QOL in epilepsy patients
in Russia in the literature in English.Methods
Evaluation of 242 patients with epilepsy (age 15—59;
120 men and 122 women) in Moscow was performed.
This group consisted of patients revealed in several
neighboring regions of Moscow during epidemiology
study. Patients revealed during the epidemiologystudy formed a substantial proportion (more than
70%) of patients included in this study. The epide-
miology study in Moscow is a fragment of the Pro-
gram of epidemiology study in Russia, performed
during 5 years in different regions of the country.
Within this study different methods of data collec-
tion have been used, including data collection from
outpatient neurology and psychiatry departments, a
record of emergency calls for seizures in the public
places, interviews during the door-to-door studies.
Patients revealed during this study were then inves-
tigated in the Department of Neurology and Neuro-
surgery of the Russian State Medical University.
Another part of patients, included in this study,
was referred to our department by local physicians
(general practitioners, neurologists, psychiatrists,
etc., without any specialization in epileptology) for
diagnosis and/or treatment.
To confirm that the patient’s population was not a
population of difficult-to-treat patients, we would
like to mention that after one-year of follow-up on
the improved therapy (mostly on CBZ or VPA) more
then 60% epilepsy patients were seizure-free.
As mentioned no special selection was done; only
patients with another progressive neurological or
psychiatric illness, severe somatic pathology or
mentally disabled were excluded from the study.
We used QOLIE-31 scale of quality of life10 which
is the modified version of QOLIE-89.6 QOLIE-31 con-
sists of 31 questions divided into 7 groups (sub-
scales). Our group has previously done the cross-
cultural adaptation of this scale into the Russian
language.
The method of translation and cultural adapta-
tion, as described by Cramer et al.,7 consisted
of two independent forward translations into Rus-
sian by professional translators native in Russian,
then the reconciled version was developed during
the meeting between the forward translation and
QOL researchers. Thereafter the reconciled trans-
lation was backtranslated into English by another
professional translator. After second reconciliation
meeting the scale was tested in 10 patients to
assess clarity, appropriateness of wording, under-
standability and cultural relevance of the trans-
lated version. The final step was the meeting
between the translators and QOL researchers to
ensure that the original questionnaire and the
translations measure the same concepts. This pro-
cedure has been performed in collaboration with
Dr. J. Cramer.
In the present study, we accounted the score of
the each subscale and total score; higher scores
indicated better quality of life. Subscales assessed
such items as Seizure Worry, Overall Quality of
Life (Overall QOL), Emotional Well-being, Energy/
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Table 1 Demographic characteristics
Age (years)
Mean  S.D. 35.86  17.56
Gender, n (%)
Male 120 (49.6)
Female 122 (50.4)
Duration of disease
Mean  S.D. 9.74  10.12
Previously treated, n (%)
Yes 144 (59.5)
No 98 (40.5)
Type of epilepsy, n (%)
Partial symptomatic 98 (40.5)
Partial cryptogenic 116 (47.9)
Generalized (idiopathic) 28 (11.6)Fatigue, Cognitive Functioning, Medication Effects
and Social Functioning. The patients were divided
into two groups: ‘‘de novo’’ (newly diagnosed
epilepsy patient) (n = 98) and previously treated
(n = 144).
We analyzed HRQOL patients with epilepsy (by
QOLIE-31 questionnaire) in dependence of (1) fre-
quency; (2) duration of disease. Depression in our
patients was also assessed; it was diagnosed accord-
ing to ICD-10 criteria. Beck Depression Inventory
was administered. But in our study were revealed
only few epilepsy patients with depression and they
were excluding from following analysis. We plan
more thorough studies of depression and anxiety
in epilepsy patients using different scales.
Statistical analysis was done by ‘‘SPSS for Win-
dows’’ of ‘‘SPSS’’ (1999) with processing of data by
methods of variation statistics including measuring
of mean scores, standard deviations and other para-
meters. For revealing connection between two or
more quantitative factors the method of stepwise
regression and R-multiple correlation coefficient
were used.Table 2 Comparison of treated and previously untreated e
De novo (n = 98)
Age (years)
Mean  S.D. 39.47  20.06
Duration of disease
Mean  S.D. 3.71  3.39
Frequency of seizures (%)
>4 within last 2 months 41.8
<4 within last 2 months 58.2
Total score of quality of life
Mean  S.D. 42.1  3.8Results
Two hundred and forty two patients were investi-
gated (Table 1). One hundred and forty four patients
(previously treated group) were with pre-existing
diagnosis of epilepsy and received antiepileptic drug
(AED) treatment previously initiated in other insti-
tutions. Unfortunately in the most cases these ther-
apy regimens were suboptimal: 77 patients (53.5%)
received inadequate (usually low doses) polyther-
apy: 56 patients (38.9%) were on 2 AED, 13 patients
(9.0%)–—on 3 AED, 8 patients (5.6%)–—on 4 AED; 67
patients (46.5%) received inadequate monotherapy.
The duration of the disease in the previously treated
group was from 2 to 15 years.
Ninety-eight patients with the duration from 0.5
to 5 years in most cases were untreated. These
patients were newly diagnosed in our Department
(‘‘de-novo’’ group). The comparison of clinical fea-
tures of these groups is shown in the Table 2.
Twenty eight patients (11.6%) were classified as
having idiopathic epilepsy, 116 (47.9%) as having
cryptogenic epilepsy, 98 (40.5%) as having sympto-
matic epilepsy. Magnetic resonance imaging in
patients with partial symptomatic epilepsy revealed
various structural pathology (lobar atrophy, brain
cysts, usually of post-stroke origin, low-grade
glioma, in some cases-mesial temporal sclerosis,
cortical displasia).
Seizures occurred several times per week in 140
(57.9%) patients, 47 (19.4%) had several seizures per
month, 31 (12.8%) had 7—12 seizures per year, 13
(5.4%) had 1—2 seizures per year and 11 (4.5%) had
been completely seizure-free in the previous 12-
month period. Frequency of seizures was higher in
the group of previously treated patients, as shown in
the Table 2. These patients had longer duration of
epilepsy, and, as mentioned, they received subop-
timal therapy for several years.
Mean total score of the quality of life in patients
with epilepsy by QOLIE-31 scale was 42.13  4.14pileptic patients
Previously treated (n = 144) All (n = 242)
33.47  15.34 35.86  17.56
13.85  11.09 9.74  10.12
100 76.4
— 23.6
42.2  5.2 42.13  4.14
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Table 3 Comparison of quality of life (by subscales) in de novo and previously treated epilepsy patients
Subscales De novo (n = 98) (M  S.D.) Previously treated (n = 144) (M  S.D.) p-Value
Seizure worry 44.81  5.94 45.85  6.20 NS
Emotional well-being 36.32  6.82 39.91  6.17 p < 0.001
Overall QOL 35.61  5.92 36.78  7.06 NS
Energy/fatigue 42.65  5.99 44.00  5.93 NS
Cognitive functioning 47.60  8.61 45.44  6.74 p < 0.05
Medical effects 53.48  9.75 55.07  7.83 NS
Social functioning 39.11  5.83 38.94  5.35 NS
Total score 42.1  3.8 42.3  5.3 NS
Table 4 Comparison of quality of life (by subscales) in epilepsy patients treated by monotherapy and by polytherapy
Subscales Monotherapy (n = 67) (M  S.D.) Polytherapy (n = 77) (M  S.D.) p-Value
Seizure worry 45.51  6.17 45.67  6.21 NS
Emotional well-being 39.37  6.66 39.96  5.56 NS
Overall QOL 37.53  6.97 35.84  7.03 NS
Energy/fatigue 43.31  5.27 43.50  4.80 NS
Cognitive functioning 46.04  7.37 45.15  7.07 NS
Medical effects 54.56  7.37 56.65  8.43 NS
Social functioning 38.89  6.00 39.17  5.22 NS
Total score 42.2  3.9 42.0  4.2 NS
Table 5 Relationship (R-multiple correlation coeffi-
cient) of quality of life (QOLIE-31) and seizure fre-
quency and duration of diseases in epilepsy patients
(N = 242)
Subscale Seizure
frequency
Duration
of disease
Seizure worry 0.22 * NS
Overall QOL 0.24 * 0.28 *
Energy/fatigue 0.28 * 0.20 **
Cognitive functioning 0.30 * NS
Medication effects 0.26 * 0.22 *
Emotional well-being NS NS
Social functioning 0.24 * 0.26 *
*p < 0.001, **p < 0.01, NS: non-significant.and it was almost equal in previously treated and
untreated patients. Comparison of QOL subscale
values is presented in the Table 3. Statistically
significant differences in quality of life (assessed
by subscales) were only in Emotional Well-Being and
Cognitive functioning subscales but these differ-
ences were minimal from the clinical point of view.
The comparison of patients on suboptimal mono
and polytherapy has been performed, but there was
no significant difference for QOL (Table 4).
We analyzed relationship between quality of life
(total score) and frequency of seizures and duration
of disease in all patients. We revealed that fre-
quency of seizures was the most significant para-
meter related to QOL (R = 0.46). Duration of disease
also correlated with QOL score (R = 0.24) (all corre-
lations are negative and highly significant with
p < 0.001).
Also significant but rather weak association
between frequency of seizures and subscales of
quality of life (with the exception of Emotional
Well-being subscale) in all patients was noticed
(Table 5). Duration of epilepsy correlated with less
number of subscales: Energy/fatigue, Medication
effects, Social functioning, Overall QOL subscales.
We separately investigated factors influencing on
HRQOL in the group of patients with epilepsy ‘‘de
novo’’. The results were further compared with
those in the group of previously treated patients.
The most relevant factor for QOL in previously
untreated patients was also frequency of seizures
(R = 0.42 with total score, p < 0.001). There wasweaker correlation between frequency of seizures
and score of Social functioning subscale (R = 0.37,
p < 0.001). Duration of disease was not significantly
associated with the total score of HRQOL in this
group.
In the group of previously treated patients fre-
quency of seizures influenced on QOL (R = 0.48 with
total score, p < 0.001). Correlations between dura-
tion of disease and total score of HRQOL were
insignificant. In the group of previously treated
patients the significant but rather weak influence
of frequency of seizures on quality of life was
noticed by the following subscales: Energy/Fatigue,
Medication Effects, Emotional Well-being, Social
Functioning (Table 6). We did not reveal any sig-
nificant correlation between frequency of seizures
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Table 6 Relationship (R-multiple correlation coeffi-
cient) of quality of life (QOLIE-31) and seizure frequency
in previously treated epilepsy patients (N = 144)
Subscale Seizure frequency
Seizure worry NS
Overall QOL NS
Energy/fatigue 0.17 **
Cognitive functioning NS
Medication effects 0.22 **
Emotional well-being 0.36 *
Social functioning 0.31 *
*p < 0.001, **p < 0.01, NS: non-significant.and subscales Seizure Worry, Overall QOL and
Cognitive Functioning.Discussion
Epilepsy is one of the most common and challenging
neurologic disorders. The main disturbances, sei-
zures, in patients with epilepsy appear episodically
but they are so substantial for patients and often
absolutely change the whole lifestyle that assess-
ment of quality of life of patients with epilepsy is
really important. Need of investigation of influence
of epilepsy on psychosocial aspect of life of patients
is apparent.1,18,20 Optimal quality of life is one of
the main goals of antiepileptic therapy.9 Improving
health-related quality of life (HRQOL) was recog-
nized as an essential component of management of
patients with epilepsy.21
Previous studies of QOL in people with epilepsy,
performed mostly in Western Europe and North
America, have highlighted diminished QOL. It was
demonstrated that Quality of life was worse in
patients with epilepsy than in the general popula-
tion; it was comparable or worse in patients
with epilepsy than that in patients with other
chronic conditions; and it was similar to that of
healthy persons in patients with well-controlled
epilepsy.2,30
Up to now there are no published in the English
literature data concerning the QOL in people with
epilepsy in Russia. The present study was focused on
investigation of QOL of patients with epilepsy in
Russia and comparison of the most important clin-
ical factors influencing on quality of life in newly
diagnosed and previously treated epilepsy patients.
According to Cramer et al.6 usually the total
QOL-31 score in epilepsy patients varied from 40
to 60 points. In our patients the total score of QOL
was rather low–—42.13  4.14.
Studies revealed that the most important for
patients with epilepsy were social and psychologicalaspects of daily life: frequency of seizures, effect of
antiepileptic drugs.8,23,25 Frequency of seizures was
described as one of the most relevant determinants
of poor QOL scores.17,27
We revealed that the following significant factors
influenced on HRQOL of our patients: frequency of
seizures and duration of disease. The most impor-
tant parameter determining quality of life was the
frequency of seizures. Duration of the disease lesser
influenced on the HRQOL.
We demonstrated that frequency of seizures was
the significant predictor of QOL in both groups:
previously suboptimally treated (without significant
difference on mono and polytherapy) and newly
diagnosed. In both groups of our patients seizure
frequency was substantial, though higher in pre-
viously treated patients. Long history of subopti-
mally treated epilepsy might have contributed to
high seizure frequency in this group. It is important
to mention that many untreated patients also had
rather long duration of epilepsy, as demonstrated in
the Table 2, that could explain frequent seizures in
this group of patients also. These findings demon-
strate that there is a substantial need for improve-
ment of the system of epilepsy care (both in the field
of diagnosis and proper treatment) in the country.
People with epilepsy frequently report dimin-
ished socialization, negative self image, feeling of
stigmatization, reduced earnings potential, and
diminished hope and ambition.11,15 We revealed
significant but rather weak dependence between
frequency of seizures and subscales of quality of
life: Seizure worry, Overall QOL, Energy/fatigue,
Cognitive functioning, Medication effects, Social
functioning. High seizure frequency limits usual
daily activity and leads to impairment of physical,
social and emotional functioning and finally to gen-
eral deterioration of one’s quality of life. Social
functioning could be the most vulnerable parameter
as in newly diagnosed patients with epilepsy
frequency of seizures influenced only on social func-
tioning subscale.
In the group of previously treated patients the
correlation between frequency of seizures and
Social Functioning and Emotional Well-Being sub-
scales were the most relevant and also indicating
the significance of social activity for the person with
epilepsy. Though attitudes toward people with epi-
lepsy have improved over the years for many people
with epilepsy stigma continues to adversely impact
their psychological wellbeing and quality of life. It is
the true for Russia as well as for many other coun-
tries. Stigma can be one of the most distressing
consequences of having seizures. Neither informal
stigma nor formal discrimination is inevitable for
epilepsy patients; however, for many individuals,
Factors influencing on quality of life in people with epilepsy 133epilepsy remains a defining feature of their identity
and such issues are a source of considerable concern
for a number of patients.14Conclusions
In epilepsy patients in Russia the total score of
QOLIE-31 was rather low–—42.13  4.14 (compared
to data from the USA).6 Frequency of seizures was
the most important factor influencing QOL in
patients with epilepsy (newly diagnosed and pre-
viously treated).Acknowledgment
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